share_log
下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Market Chatter: Moderna Rejects China's Request To Transfer COVID-19 Vaccine Technology Amid Safety Woes

市场议论:Moderna在安全困境中拒绝中国转让新冠肺炎疫苗技术的请求

MT Newswires ·  10/03 11:38

11:36 PM EDT, 10/02/2022 (MT Newswires) -- Moderna's (0QF.F) bid to distribute its mRNA-based COVID-19 jab in China ended after it declined to provide its vaccine technology to the government over commercial and safety concerns, London's Financial Times reported Sunday.

The US-based biotech has "given up" on initial efforts to sell its COVID-19 vaccine in China due to the requirement to transfer the technology before being allowed to distribute the product in the country. The company's management is reportedly wary of possible reputational damage if its local partner mishandles the manufacturing.

One of the sources noted that earlier negotiations occurred from 2020 to 2021, adding that Moderna remains "eager" to distribute its vaccine in China.

At the close of Sept. 30, Moderna shares gained over 5%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。